

Edgar Filing: ACAMBIS PLC - Form 6-K

ACAMBIS PLC  
Form 6-K  
February 06, 2006

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13s - 16 or 15d - 16 of  
the Securities Exchange Act of 1934

For the month of January 2006

Acambis plc  
(Translation of registrant's name into English)

Peterhouse Technology Park  
100 Fulbourn Road  
Cambridge CB1 9PT  
England

(address of principal executive offices)

(Indicate by check mark whether the registrant files or will file annual  
reports under cover of Form 20-F or Form 40-F

Forms 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934).

Yes  No

(if "Yes" is marked, indicate below the file number assigned to the registrant  
in connection with Rule 12g3-2(b): 82- ).

Enclosures:

1. Blocklisting Interim Review
2. Holding(s) in Company

SCHEDULE 5

BLOCKLISTING SIX MONTHLY RETURN

1. Name of company  
Acambis plc
2. Name of scheme  
Acambis 1996 Approved Share Option Scheme

## Edgar Filing: ACAMBIS PLC - Form 6-K

3. Period of return: From 01 July 2005 to 31 December 2005

4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at end of last period:

370,069

5. Number of shares issued/allotted under scheme during period:

8,140

6. Balance under scheme not yet issued/allotted at end of period:

361,929

7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission:

33,916,280 ordinary shares of 10p each

Date of admission: 30 November 1995

Please confirm total number of shares in issue at the end of the period in order for us to update our records:

107,351,407

1. Name of company

Acambis plc

2. Name of scheme

Acambis 1995 Savings-Related Share Option Scheme

3. Period of return: From 01 July 2005 to 31 December 2005

4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at end of last period:

84,690

5. Number of shares issued/allotted under scheme during period:

9,765

6. Balance under scheme not yet issued/allotted at end of period:

74,925

7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission:

33,916,280 ordinary shares of 10p each

Date of admission: 30 November 1995

Please confirm total number of shares in issue at the end of the period in order for us to update our records:

107,351,407

1. Name of company

Acambis plc

2. Name of scheme

Acambis 1999 Share Option Plan

3. Period of return: From 01 July 2005 to 31 December 2005

4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at end of last period:

538,073

## Edgar Filing: ACAMBIS PLC - Form 6-K

5. Number of shares issued/allotted under scheme during period:

4,000

6. Balance under scheme not yet issued/allotted at end of period:

534,073

7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission:

33,916,280 ordinary shares of 10p each

Date of admission: 30 November 1995

Please confirm total number of shares in issue at the end of the period in order for us to update our records:

107,351,407

1. Name of company

Acambis plc

2. Name of scheme

OraVax 1990 Stock Incentive Plan

3. Period of return: From 01 July 2005 to 31 December 2005

4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at end of last period:

143,706

5. Number of shares issued/allotted under scheme during period:

Nil

6. Balance under scheme not yet issued/allotted at end of period:

143,706

7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission:

33,916,280 ordinary shares of 10p each

Date of admission: 30 November 1995

Please confirm total number of shares in issue at the end of the period in order for us to update our records:

107,351,407

1. Name of company

Acambis plc

2. Name of scheme

OraVax 1995 Stock Incentive Plan

3. Period of return: From 01 July 2005 to 31 December 2005

4. Number and class of shares(s) (amount of stock/debt security) not issued under scheme at end of last period:

104,179

5. Number of shares issued/allotted under scheme during period:

Nil

6. Balance under scheme not yet issued/allotted at end of period:

104,179

## Edgar Filing: ACAMBIS PLC - Form 6-K

7. Number and class of share(s) (amount of stock/debt securities) originally listed and the date of admission:  
33,916,280 ordinary shares of 10p each

Date of admission: 30 November 1995

Please confirm total number of shares in issue at the end of the period in order for us to update our records:  
107,351,407

Contact for queries: Elizabeth Brown  
Address: Acambis plc, Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT  
Name of person making return: Elizabeth Brown  
Telephone: 01223 275300  
Position of person making return: Company Secretary  
Date of return: 9 January 2006

### Holding in Company

Cambridge, UK and Cambridge, Massachusetts - 18 January 2006 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The Goldman Sachs Group, Inc.

On 16 January 2006, Acambis received notification that, as of the close of business on 12 January 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85 Broad Street, New York, NY 10004, USA, was interested in a total of 4,258,375 ordinary shares of 10p each, representing a 3.97% holding of Acambis' issued share capital.

Of these 4,258,375 shares:

a) the interest in 261,315 shares arose from an interest held by Goldman, Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as custodian; these shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited ("GSSN");

b) the interest in 625,400 shares arose from an interest held by GS&Co, acting as custodian of 312,700 American Depositary Receipts ("ADRs"); these ADRs are, or will be, held at The Depository Trust Company, New York;

c) the interest in 200 shares arose from a beneficial interest in 100 ADRs held by GS&Co; these ADRs are, or will be, held at the DTC;

d) the interest in 47,630 shares arose from the interest held by GS&Co., a direct subsidiary of GS Inc, acting as discretionary manager. These shares are, or will be, registered in the name of GSSN; and

e) the interest in 3,323,830 shares arose from a beneficial interest held by Goldman Sachs International, a direct subsidiary of GS Inc; these shares are, or will be, registered at CREST in account CREPTMP.

-ends-

Enquiries:

## Edgar Filing: ACAMBIS PLC - Form 6-K

Acambis plc

Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300

Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275 300

### About Acambis

Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Recognised internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world. It is also developing an attenuated smallpox vaccine, MVA3000, under contracts with the US National Institutes of Health. Acambis is establishing a travel vaccines franchise through its US-based subsidiary Berna Products Corporation, which markets Vivotif(R), the world's only licensed oral typhoid vaccine, in North America. Acambis has other potential travel vaccines in development and is also developing an investigational vaccine against the West Nile virus, which has spread to 48 US States in the last six years.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary listing is on the London Stock Exchange (ACM) and its shares are listed in the form of American Depositary Receipts on NASDAQ (ACAM). More information is available at [www.acambis.com](http://www.acambis.com).

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing and commercialisation risks, the risks of satisfying the regulatory approval process in a timely manner, the need for and the availability of additional capital. For a discussion of these and other risks and uncertainties see "Risk management" in the Company's 2004 Annual Report and "Risk factors" in the 2004 Form 20-F, in addition to those detailed on the Company's website and in the Company's filings made with the Securities and Exchange Commission from time to time. These forward-looking statements are based on estimates and assumptions made by the management of Acambis and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant Peptide Therapeutics Group has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 31 January 2006

ACAMBIS PLC

Edgar Filing: ACAMBIS PLC - Form 6-K

By: /s/ Lyndsay Wright  
Name: Lyndsay Wright  
Title: VP, Communications and IR.